Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Cimetidine or its salts..

when sold in concentrations of 100 mg or less per dosage unit and indicated for the treatment of heartburn

III DEC / 13
Cinacalcet or its saltsPDL I DEC / 13
Cinchocaine (dibucaine) and its salts for ophthalmic or parenteral use II SEP / 98
Cinchophene or its saltsPDL I DEC / 13
Cinnamedrine U
CinoxacinPDL I DEC / 13
Ciprofloxacin or its saltsPDL I DEC / 13
Cisapride or its saltsPDL I SEP / 98
Cisatracurium besilatePDL I DEC / 13
CisplatinPDL I DEC / 13
Citalopram or its saltsPDL I DEC / 13
Cladribine or its salts or derivativesPDL I DEC / 13
Clemastine and its salts III SEP / 98
Clenbuterol or its saltsPDL I DEC / 13
Clevidipine or its saltsPDL I DEC / 13
Clidinium and its salts II SEP / 98
Clobazam and its saltsTS I SEP / 98
Clobetasone butyrate when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin II OCT / 06
Clodronic acid or its saltsPDL I DEC / 13
ClofarabinePDL I DEC / 13
ClofibratePDL I DEC / 13
Clomiphene or its saltsPDL I DEC / 13
Clomipramine or its saltsPDL I DEC / 13
Clonazepam and its saltsTS I SEP / 98
Clonidine or its saltsPDL I DEC / 13
ClonitazeneN I JUN / 02
Clopidogrel or its saltsPDL I DEC / 13
ClorazepateTS I JUN / 02
Clorazepic acid or its saltsPDL I DEC / 13
Closantel or its saltsPDL

for veterinary use, including but not limited to closantel sodium

I AUG / 16
ClostebolC3 I JUN / 02
Clotiazepam and any salt thereofTS I JUN / 02
Clotrimazole and its salts.. for human use in preparations for topical use U DEC / 13
Clotrimazole or its saltsPDL

for human use, except in preparations for topical or vaginal use

I DEC / 13
Clotrimazole or its salts.

for human use in preparations for intra-vaginal use

III DEC / 13
CloxazolamTS I JUN / 02
Clozapine or its saltsPDL I DEC / 13
Coal tar in concentrations of more than 10% II SEP / 98
Coal tar. in concentrations up to and including 10% U
Cobicistat or its saltsPDL I DEC / 18
Cobimetinib or its saltsPDL I AUG / 16
Coca leavesN I JUN / 02
Cocaine (benzoylmethylecgonine)N Subject to Section 2 (2) of the Narcotic Control Regulations (NCR) and Section J of the Food and Drug Regulations (FDR) as of 23 October 2013. I JUN / 02
CodeineN I JUN / 02
Codeine and its salts in preparations exempted from the Regulations to the Controlled Drugs and Substances Act II SEP / 98
CodoximeN I JUN / 02
ColchicinePDL I DEC / 13
Colesevelam or its saltsPDL

including but not limited to colesevelam hydrochloride

I DEC / 13
Colestipol or its saltsPDL I DEC / 13
Colfosceril or its derivativesPDL I DEC / 13
Colistin or its salt or derivativesPDL

including but not limited to colistimethate

I DEC / 13
CollagenasePDL

when recommend for the debridement of severe burns and skin ulcers

I DEC / 13
Copper chloride (cupric chloride) in injectable form for parenteral nutrition I JAN / 03
Copper sulfate in injectable form for parenteral nutrition I JAN / 03
CrisaborolePDL I JUL / 18
Crizotinib or its salts or derivativesPDL I DEC / 13
Cromoglicic (cromoglycic) acid or its saltsPDL

except sodium cromoglicate (cromoglycate) in solutions for ophthalmic or nasal use in concentrations of 2% or less [*see sodium cromoglicate (cromoglycate)]

I DEC / 13
Crotamiton II SEP / 98
Cyclandelate II SEP / 98
Cyclazocine and its salts II SEP / 98
CyclizinePDL

for human use

I DEC / 13
CyclobarbitalC2 I JUN / 02
Cyclobenzaprine or its saltsPDL I DEC / 13
Cyclomethacaine and its salts for ophthalmic or parenteral use II SEP / 98
CyclopalC2 I JUN / 02
Cyclopentamine and its salts II SEP / 98
Cyclopentolate or its salts except in products for ophthalmic or parenteral use II SEP / 98
Cyclopentolate or its saltsPDL

in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada

I DEC / 13
CyclophosphamidePDL I DEC / 13
CycloserinePDL I DEC / 13
CyclosporinePDL

including but not limited to ciclosporin

I DEC / 13
Cyproheptadine and its salts II SEP / 98
Cyproterone acetatePDL

including but not limited to cyproterone acetate

I DEC / 13
Cysteamine (Mercaptamine) or its saltsPDL I AUG / 17
Cytarabine or its saltsPDL I DEC / 13
Cytomegalovirus immune globulins I FEB / 02
Dabigatran or its salts or derivativesPDL

including but not limited to dabigatran etexilate

I DEC / 13
Dabrafenib or its saltsPDL I DEC / 13
DacarbazinePDL I DEC / 13
Daclatasvir or its saltsPDL I OCT / 15
DaclizumabPDL I DEC / 13
Daclizumab betaPDL I FEB / 17
Dacomitinib or its saltsPDL I MAR / 19
DactinomycinPDL I DEC / 13
Dalbavancin or its saltsPDL I OCT / 18
Dalfopristin or its saltsPDL I DEC / 13
Dalteparin or its saltsPDL I DEC / 13
Danaparoid or its salts or derivativesPDL I DEC / 13
DanazolPDL I DEC / 13
Danofloxacin or its saltsPDL I DEC / 13
Danthron III SEP / 98
Dantrolene or its saltsPDL I DEC / 13
Dapagliflozin or its derivativesPDL I MAR / 15
Dapiprazole or its saltsPDL I DEC / 13
DaptomycinPDL I DEC / 13
DaratumumabPDL I AUG / 16
Darifenacin or its saltsPDL I DEC / 13
DarolutamidePDL I JUL / 20
DarunavirPDL I DEC / 13
Dasabuvir or its saltsPDL I MAR / 15

2008 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled